PDGFRB and pulmonary arterial hypertension: Seralutinib is a small-molecule, highly potent PDGFRα/PDGFRβ, CSF1R, and c-KIT kinase inhibitor specifically designed for inhalation to treat PAH locally with limited systemic exposure (Figure 1) [7].